{"id":22691,"date":"2022-10-20T05:08:00","date_gmt":"2022-10-19T21:08:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=22691"},"modified":"2022-10-20T07:53:53","modified_gmt":"2022-10-19T23:53:53","slug":"nejm%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87-%e5%b8%a6%e6%9c%89%e5%a5%a5%e5%af%86%e5%85%8b%e6%88%8e%e7%9a%84%e4%ba%8c%e4%bb%b7%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e7%96%ab%e8%8b%97%e5%8a%a0%e5%bc%ba","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=22691","title":{"rendered":"[NEJM\u53d1\u8868\u8bba\u6587]: \u5e26\u6709\u5965\u5bc6\u514b\u620e\u7684\u4e8c\u4ef7\u65b0\u51a0\u75c5\u6bd2\u75ab\u82d7\u52a0\u5f3a\u9488"},"content":{"rendered":"\n

ORIGINAL ARTICLE<\/a><\/p>\n\n\n\n

A Bivalent Omicron-Containing Booster Vaccine against Covid-19<\/h1>\n\n\n\n

Spyros Chalkias, Charles Harper, Keith Vrbicky,\u00a0et al<\/h3>\n\n\n\n

N Engl J Med September 16, 2022
DOI: 10.1056\/NEJMoa2208343<\/h3>\n\n\n\n

Abstract<\/h2>\n\n\n\n

BACKGROUND<\/h2>\n\n\n\n

The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.<\/p>\n\n\n\n

METHODS<\/h2>\n\n\n\n

In this ongoing, phase 2\u20133 study, we compared the 50-\u03bcg bivalent vaccine mRNA-1273.214 (25 \u03bcg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-\u03bcg mRNA-1273 booster. We administered mRNA-1273.214 or mRNA-1273 as a second booster in adults who had previously received a two-dose (100-\u03bcg) primary series and first booster (50-\u03bcg) dose of mRNA-1273 (\u22653 months earlier). The primary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 28 days after the booster dose.<\/p>\n\n\n\n

RESULTS<\/h2>\n\n\n\n

Interim results are presented. Sequential groups of participants received 50 \u03bcg of mRNA-1273.214 (437 participants) or mRNA-1273 (377 participants) as a second booster dose. The median time between the first and second boosters was similar for mRNA-1273.214 (136 days) and mRNA-1273 (134 days). In participants with no previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the geometric mean titers of neutralizing antibodies against the omicron BA.1 variant were 2372.4 (95% confidence interval [CI], 2070.6 to 2718.2) after receipt of the mRNA-1273.214 booster and 1473.5 (95% CI, 1270.8 to 1708.4) after receipt of the mRNA-1273 booster. In addition, 50-\u03bcg mRNA-1273.214 and 50-\u03bcg mRNA-1273 elicited geometric mean titers of 727.4 (95% CI, 632.8 to 836.1) and 492.1 (95% CI, 431.1 to 561.9), respectively, against omicron BA.4 and BA.5 (BA.4\/5), and the mRNA-1273.214 booster also elicited higher binding antibody responses against multiple other variants (alpha, beta, gamma, and delta) than the mRNA-1273 booster. Safety and reactogenicity were similar with the two booster vaccines. Vaccine effectiveness was not assessed in this study; in an exploratory analysis, SARS-CoV-2 infection occurred in 11 participants after the mRNA-1273.214 booster and in 9 participants after the mRNA-1273 booster.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

CONCLUSIONS<\/h2>\n\n\n\n

The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns. (Funded by Moderna; ClinicalTrials.gov number, NCT04927065. opens in new tab<\/a>.)<\/p>\n","protected":false},"excerpt":{"rendered":"

ORIGINAL ARTICLE A Bivalent Omicron-Containing Booster […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/22691"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22691"}],"version-history":[{"count":1,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/22691\/revisions"}],"predecessor-version":[{"id":22692,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/22691\/revisions\/22692"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}